Results 241 to 250 of about 508,501 (339)

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Star Power: Early life stages of an endangered sea star are robust to current and near-future warming. [PDF]

PLoS One
Hodin J, Anteau FP, Ashcraft BF, Brito M, Curliss F, Kalytiak-Davis AR, Peng JS, Schwab CJ, Valdez VV, Weertman W.   +9 more
europepmc   +1 more source

Application of Multiple-imputation-particle-filter for Parameter Estimation of Visual Binary Stars with Incomplete Observations

, 2016
Rubén M. Clavería, David E. Acuña-Ureta, R. A. Méndez, Jorge F. Silva, Marcos E. Orchard   +4 more
openalex   +2 more sources

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial. [PDF]

J Immunother Cancer
Saad MB, Showkatian E, Verma V, Al-Tashi Q, Aminu M, Xu X, Qayati Mohamed M, Salehjahromi M, Sujit SJ, Kitsel Y, Lin SH, Liao Z, Gandhi S, Qian D, Jaffray D, Chung C, Vokes NI, Zhang J, Lee JJ, Heymach JV, Wu J, Chang JY.   +21 more
europepmc   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

A systematic review of the association between ultrasound-detected features and laboratory inflammatory biomarkers in hand osteoarthritis. [PDF]

Ann Med
Alshalawi O, Fulford J, Al-Shaari H, Kemp MC, Obotiba AD.   +4 more
europepmc   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

Unusual Large Multicavitated Left Ventricular Pseudoaneurysm After Myocardial Infarction. [PDF]

JACC Case Rep
Rasheed S, Kumar M, Zahra K, Zubair M, Yousafzai E, Ali D, Faheem R, Ullah N, Akhtar P.   +8 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source